Drug name - Ibsrela
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8541448 | ARDELYX INC | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
Dec, 2029
(7 years from now) | |
| US8969377 | ARDELYX INC | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
Dec, 2029
(7 years from now) | |
| CN102333759A | ARDELYX INC | Compounds And Methods For Inhibiting Nhe-Mediated Antiport In The Treatment Of Disorders Associated With Fluid Retention Or Salt Overload And Gastrointestinal Tract Disorders |
Oct, 2014
(7 years ago) | |
| CN103819403B | ARDELYX INC | Compounds And Methods For Inhibiting Nhe-Mediated Antiport In The Treatment Of Disorders Associated With Fluid Retention Or Salt Overload And Gastrointestinal Tract Disorders |
Dec, 2029
(7 years from now) | |
| CN103819403A | ARDELYX INC | Compounds And Methods For Inhibiting Nhe-Mediated Antiport In The Treatment Of Disorders Associated With Fluid Retention Or Salt Overload And Gastrointestinal Tract Disorders |
Dec, 2029
(7 years from now) | |
| IN329133B | ARDELYX INC | Compounds And Methods For Inhibiting Nhemediated Antiport In The Treatment Of Disorders Associated With Fluid Retention Or Salt Overload And Gastrointestinal Tract Disorders |
Dec, 2029
(7 years from now) | |
| IN201105002P4 | ARDELYX INC | Compounds And Methods For Inhibiting Sodium Hydrogen Exchanger-Mediated Antiport In Treatment Of Disorders Associated With Fluid Retention Or Salt Overload And Gastrointestinal Tract Disorders |
Dec, 2029
(7 years from now) | |
| EP3351248B1 | ARDELYX INC | Compounds And Methods For Inhibiting Nhe-Mediated Antiport In The Treatment Of Disorders Associated With Fluid Retention Or Salt Overload And Gastrointestinal Tract Disorders |
Dec, 2029
(7 years from now) | |
| EP2384318B1 | ARDELYX INC | Compounds And Methods For Inhibiting Nhe-Mediated Antiport In The Treatment Of Disorders Associated With Fluid Retention Or Salt Overload And Gastrointestinal Tract Disorders |
Dec, 2029
(7 years from now) | |
| EP3351248A1 | ARDELYX INC | Compounds And Methods For Inhibiting Nhe-Mediated Antiport In The Treatment Of Disorders Associated With Fluid Retention Or Salt Overload And Gastrointestinal Tract Disorders |
Dec, 2029
(7 years from now) | |
| EP2384318A2 | ARDELYX INC | Compounds And Methods For Inhibiting Nhe-Mediated Antiport In The Treatment Of Disorders Associated With Fluid Retention Or Salt Overload And Gastrointestinal Tract Disorders |
Dec, 2029
(7 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9408840 | ARDELYX INC | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorder |
Dec, 2029
(7 years from now) | |
| US9006281 | ARDELYX INC | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
May, 2030
(7 years from now) | |
Drugs and Companies using TENAPANOR HYDROCHLORIDE ingredient
Treatment: Method of treating irritable bowel syndrome with constipation by administering tenapanor
Dosage: TABLET;ORAL
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| EQ 50MG BASE | TABLET;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.